Releases - Zealand Pharma A/S

View:
 

Found press releases

 

Zealand informs of new Sanofi scientific presentations for Lyxumia® and of own p...

6/17/2013 1:30 AM EST
Zealand Pharma A/S
Press release

Zealand informs of new Sanofi scientific presentations for Lyxumia® and of own
presentation of a novel Zealand liquid glucagon analogue at the ADA’s 73rd
Scientific Sessions

Copenhagen, 2013-06-17 07:30 CEST (GLOBE NEWSWIRE) -- - Scientific data on the
post-prandial mechanism of action of Lyxumia® to be presented

- Zealand to present own new data on a novel liquid glucagon...

Zealand enters collaboration with D. E. Shaw Research with the objective of addi...

6/12/2013 8:00 AM EST
Zealand Pharma A/S
Press release

Zealand enters collaboration with D. E. Shaw Research with the objective of
adding a new dimension to peptide drug design

Copenhagen, 2013-06-12 14:00 CEST (GLOBE NEWSWIRE) -- - The collaboration will
combine D. E. Shaw Research’s state-of-the-art computational capabilities with
Zealand’s broad-based discovery and development competencies to form a
potential new basis for the...

Zealand’s presentation at the Jefferies 2013 Global Healthcare Conference to be ...

5/31/2013 6:08 AM EST
Zealand Pharma A/S
Investor News

Zealand’s presentation at the Jefferies 2013 Global Healthcare Conference to be
webcast

Copenhagen, 2013-05-31 12:08 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S
(NASDAQ OMX Copenhagen: ZEAL) (“Zealand”),a Danish biotechnology company
dedicated to the discovery and development of novel peptide drugs, is scheduled
to make a presentation at the Jefferies 2013 Global Healthcare...

Zealand and Helsinn announce Helsinn’s decision to advance the development of el...

5/28/2013 5:16 AM EST
Zealand Pharma A/S
Company Announcement

Zealand and Helsinn announce Helsinn’s decision to advance the development of
elsiglutide into Phase IIb for the prevention of chemotherapy-induced diarrhea

- The decision follows promising findings from a Phase IIa Proof-of-Concept
study
- Helsinn is planning a Phase IIb study with elsiglutide, and study activities
are expected to start in H2 2013

Copenhagen, Denmark...

Zealand to present at upcoming global healthcare investor conferences in the US

5/21/2013 9:00 AM EST
Zealand Pharma A/S
Investor News

Zealand to present at upcoming global healthcare investor conferences in the US

Copenhagen, 2013-05-21 15:00 CEST (GLOBE NEWSWIRE) --

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”), a Danish
biotechnology company dedicated to the discovery and development of novel
peptide drugs, informs it will present at the following upcoming healthcare
investor conferences in...

Zealand Pharma A/S - Interim report for Q1 2013 (un-audited)

5/15/2013 2:35 AM EST
Zealand Pharma A/S
Company Announcement

Zealand Pharma A/S - Interim report for Q1 2013 (un-audited)

Copenhagen, 2013-05-15 08:35 CEST (GLOBE NEWSWIRE) --

Company Announcement
No. 14/2013

- Fully in line with expectations, net result for the quarter was DKK -57
(EUR -8) million

- Cash and securities of DKK 441 (EUR 59) million on 31 March 2013

- Financial outlook for 2013 retained

- European...

Zealand announces amendments to its Articles of Association

5/8/2013 8:30 AM EST
Zealand Pharma A/S
Company Announcement

Zealand announces amendments to its Articles of Association

Copenhagen, 2013-05-08 14:30 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S
(NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) informs that the company’s Articles
of Association have been amended.

The amendments to the Articles of Association are entailed by the decision at
the company’s Annual General Meeting, held on 30...

Notice of Zealand’s Interim Report for Q1 2013

5/8/2013 4:21 AM EST
Zealand Pharma A/S
Investor News

Notice of Zealand’s Interim Report for Q1 2013

Copenhagen, 2013-05-08 10:21 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S
(NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) a Danish biotechnology company
dedicated to the discovery and development of novel peptide drugs, informs that
its interim report for the first quarter of 2013 in accordance with the
Financial Calendar will be...

Zealand Pharma announces Sanofi’s ongoing commitment to the Lantus®/Lyxumia® sin...

5/2/2013 1:38 AM EST
Zealand Pharma A/S
Company Announcement

Zealand Pharma announces Sanofi’s ongoing commitment to the Lantus®/Lyxumia®
single combination program

Priority for Phase III initiation assigned by Sanofi to the Fixed-Ratio
combination product

Copenhagen, 2013-05-02 07:38 CEST (GLOBE NEWSWIRE) -- Zealand Pharma A/S
(NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) announces that its licensing partner
Sanofi (EURONEXT:SAN...

Zealand Pharma A/S - Passing of Annual General Meeting

4/30/2013 10:30 AM EST
Zealand Pharma A/S
Company Announcement

Zealand Pharma A/S - Passing of Annual General Meeting

Copenhagen, 2013-04-30 16:30 CEST (GLOBE NEWSWIRE) --
-- All proposals from the Board of Directors were adopted
-- Following the General Meeting, the Board of Directors constituted itself
with Daniël J. Ellens as new Chairman and Jørgen Lindegaard as new Vice
Chairman

Today, Zealand Pharma A/S (NASDAQ OMX...

Zealand Pharma A/S

RSS